1. Home
  2. NRGV vs MNPR Comparison

NRGV vs MNPR Comparison

Compare NRGV & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Energy Vault Holdings Inc.

NRGV

Energy Vault Holdings Inc.

HOLD

Current Price

$3.62

Market Cap

727.0M

Sector

Miscellaneous

ML Signal

HOLD

Logo Monopar Therapeutics Inc.

MNPR

Monopar Therapeutics Inc.

HOLD

Current Price

$111.33

Market Cap

587.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRGV
MNPR
Founded
2017
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
727.0M
587.4M
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
NRGV
MNPR
Price
$3.62
$111.33
Analyst Decision
Strong Sell
Strong Buy
Analyst Count
1
11
Target Price
$2.00
$107.00
AVG Volume (30 Days)
5.2M
263.1K
Earning Date
05-05-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
28.57
54.99
EPS
N/A
N/A
Revenue
$203,671,000.00
N/A
Revenue This Year
$28.93
N/A
Revenue Next Year
$16.69
N/A
P/E Ratio
N/A
N/A
Revenue Growth
340.86
N/A
52 Week Low
$1.60
$29.18
52 Week High
$6.65
$124.82

Technical Indicators

Market Signals
Indicator
NRGV
MNPR
Relative Strength Index (RSI) 51.89 49.18
Support Level $2.95 $102.88
Resistance Level $4.11 $114.60
Average True Range (ATR) 0.32 6.56
MACD 0.07 -1.78
Stochastic Oscillator 58.65 25.29

Price Performance

Historical Comparison
NRGV
MNPR

About NRGV Energy Vault Holdings Inc.

Energy Vault Holdings Inc is a diversified portfolio of energy storage solutions to third parties, including proprietary gravity, battery, and green hydrogen-based technologies, supported by technology-agnostic energy management software and integration capabilities. Geographical presence in the United States, Australia, and other countries. The majority of its revenue comes from Australia.

About MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.

Share on Social Networks: